Gengraf Oral Solution
There is a minimal experience with cyclosporine overdosage. Forced emesis can be of value up to 2 hours after administration of Gengraf® (cyclosporine oral solution, USP [MODIFIED]). Transient hepatotoxicity and nephrotoxicity may occur which should resolve following drug withdrawal. General supportive measures and symptomatic treatment should be followed in all cases of overdosage. Cyclosporine is not dialyzable to any great extent, nor is it cleared well by charcoal hemoperfusion. The oral dosage at which half of experimental animals are estimated to die is 31 times, 39 times and > 54 times the human maintenance dose for transplant patients (6 mg/kg; corrections based on body surface area) in mice, rats, and rabbits.
Gengraf® (cyclosporine oral solution, USP [MODIFIED]) is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation.
Psoriasis patients who are treated with Gengraf® (cyclosporine oral solution, USP [MODIFIED]) should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive Gengraf®.
Last reviewed on RxList: 5/7/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Gengraf Oral Solution Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.